Matching articles for "Prometrium"

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • March 4, 2024;  (Issue 1697)
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 | Show Full IntroductionHide Full Introduction

Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • July 29, 2019;  (Issue 1577)
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and allow for more dosing flexibility.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):120 | Show Full IntroductionHide Full Introduction

Progesterone for Prevention of Premature Birth

   
The Medical Letter on Drugs and Therapeutics • May 16, 2011;  (Issue 1364)
The FDA recently approved the marketing of hydroxyprogesterone caproate injection (Makena – Ther-Rx) for prevention of preterm birth in women with a singleton pregnancy who have a history of...
The FDA recently approved the marketing of hydroxyprogesterone caproate injection (Makena – Ther-Rx) for prevention of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Med Lett Drugs Ther. 2011 May 16;53(1364):37-8 | Show Full IntroductionHide Full Introduction